Introduction
CNVs have received significant attention in recent years, in part because the increased resolution of genomic analyses has uncovered such events to be abundant in human genomes and relevant to the pathogenesis of both rare and complex traits. CNVs range in size from a kilobase (kb) to several megabases (Mb) [1 ] . Although some CNVs are found at high frequency in human populations and are thus thought to be a potential source of genetic diversity [2 ,3 ] , larger CNVs, especially de novo, are associated frequently with human disorders [4] ; in addition to the documented involvement of CNVs in birth defects (e.g. craniofacial, cardiac, respiratory, renal) [5, 6 ,7-12], CNVs are also understood to be enriched in the pathogenesis of neurodevelopmental and neurocognitive disorders, such as intellectual disability, schizophrenia, and autism spectrum disorders (ASD) [6 ,13 ,14,15,16 ,17 ,18 ,19,20] .
The increased resolution of array-comparative genomic hybridization (aCGH) has catalyzed the hyper-acceleration of CNV discovery; recent advances in exome and genome sequencing analyses are likely to increase the pace of CNV discovery further [21, 22 ] . In the midst of this progress, some acute interpretative problems have arisen. First, the rarity of most CNVs precludes their statistical analysis with regard to causality. Second, because some CNVs are mediated by non-homologous recombination-prone low copy repeats [23] [24] [25] , recurrence of such events is not deterministic of pathogenicity but reflective of local genomic architecture. Third, CNVs typically affect multiple genes, exacerbating the problem of assigning causality to particular transcripts within a CNV. Finally, the ascertainment of the clinical significance of CNVs is often complicated by clinical heterogeneity, non-penetrance and variable expressivity [13 ,26,27 ,28].
Given the above challenges, a central question pertains to the contribution of each gene within a CNV to the phenotype. This is a complex issue; each CNV presents unique characteristics and interpretations that are driven, in part, by its gene content and associated clinical phenotype. Nonetheless, our survey of the current data available has identified some patterns emerging in a subclass of CNVs for which the presence of low copy repeats induce the generation of both deletions and duplications of the same segment. Here, we synthesize our current understanding of the genetic causality of these CNVs and ask whether emergent genetic models can illuminate and predict the pathomechanisms caused by this class of genetic mutations.
Reciprocal CNVs and clinical phenotypes
An examination of known reciprocal CNVs and their associated clinical features has indicated that reciprocal CNV-induced phenotypes can be broadly classified into four general categories: mirrored (deletions and duplications of the chromosomal region have opposite effects), identical, overlapping, and unique. Examples of these classes are shown in Table 1 . ]. Adding to the complexity, the presence of that deletion in normal family members of probands, as well as in population controls, suggests that the deletion alone is not sufficient to cause intellectual disability. The reciprocal duplication is less frequent, with a few cases described to date [28, 61] . The duplication was first identified in four patients with intellectual disability, autism, hypotonia, obesity, recurrent ear infections, and low set ears [28] . However, none of these patients had structural brain abnormalities, or the epileptic seizures seen in deletion patients.
Reciprocal CNVs and genetic architecture
Are there any common patterns that can inform our understanding of the genetic drivers of the CNV-associated phenotypes for del and dup patients? Broadly, one can consider three basic models ( Figure 1 ): (a) the singlegene CNV model, in which the phenotypes of deletion (del) or dup patients are the product of dosage imbalance of a single gene; (b) the 'simplex cis epistatic' model, in which dysfunction of a single gene is necessary and sufficient to establish phenotype, but is subject to modulation by epistasis effect exerted by other genes within the CNV; and (c) the 'complex cis-epistatic' model in which phenotypes are the result of the simultaneous dosage imbalance of numerous genes within the CNV, some of which drive specific endophenotypes and some of which exhibit complex additive and/or multiplicative relationships.
Intuitively, the complexity intimated by the latter model is expected to be true and is consistent with our understanding of large genomic lesions, such as chromosomal abnormalities. For example, the additional copy of human chromosome 21 results in the increased expression of 29% of its genes; the remaining 71% of the transcripts on Chr21 are either compensated for or are highly variable among patients [62] . Thus, although most of the chromosome 21 transcripts are compensated for the gene-dosage effect, a subset of the overexpressed genes are likely major drivers and/or modulate the numerous of deleterious phenotypes observed in individuals with Down syndrome [63] . However, experimental dissection of reciprocal CNVs suggests that each of the other two models might not only be true, but in fact predominate in this class of genomic disorders. Caution is warranted, given that the number of reciprocal CNVs dissected successfully remains small and that in many instances phenotyping of patients is incomplete. Nonetheless, it is intriguing that the same paradigms are being observed in reciprocal CNVs at different regions, of different size, and with different phenotypic associations.
Reciprocal CNVs and single-gene defects
This class of CNVs is rare. Charcot-Marie-Tooth disease (CMT) is the most common hereditary motor and sensory neuropathy, and CMT type 1A (CMT1A), the most common type of CMT, is subject to a gene dosage effect [64] . The primary genetic cause of CMT1A is a duplication of PMP22 resulting from the unequal crossover between two homologous repetitive elements that flank a 1.4-Mb region of chromosome 17p12 [65] . Importantly, PMP22 frame-shift [66] and loss of function point mutations [67 ] have been found in severely affected CMT1A patients; likewise, similar loss of function point mutations in Pmp22 were found in the Trembler-J mouse, a CMT1A model [68 ] . The reciprocal deletion of PMP22 is associated with non-progressive hereditary neuropathy with liability to pressure palsies (HNPP) [69] . Overexpression of PMP22 in mice causes a defect of myelination of the neurons that recapitulates the CMT phenotype [70] whereas, as expected from human genetics, heterozygous PMP22 knockout mice revealed a pathology comparable with HNPP [71] . Although CMT1A and HNPP are not mirrored disorders per se, these data emphasize the remarkable sensitivity of myelin stability to PMP22 gene dosage, since either overexpression or underexpression results in long-term myelin instability.
Reciprocal CNVs and cis-epistasis
This appears to be the most common variety among the handful of CNVs dissected to date. The major disease candidate gene TBX1 [72] , a member of the T-box transcription factors family, is localized between LCR-A and LCR-B on 22q11.2. Notably, altering the dosage of Tbx1 (both overexpression and underexpression) recapitulates DGS and VCFS in mice [73] . Further, both loss of function mutations and mutations shown to enhance the Theoretical models to explain penetrance and phenotypic variability of reciprocal CNVs. Schematic representation of a genomic segment encompassing five genes (genes A-E) flanked by low-copy repeats (LCRs). LCRs are depicted as blue arrows with the orientation indicated by the direction of the arrowheads. Recombination between LCRs results in reciprocal deletions and duplications. The 'single gene' model posits that a single primary gene is the major driver of the phenotype; the single primary driver accounts for 100% of the expressivity and penetrance. Conversely, the cisepistasis models posit that one or multiple genes are necessary and sufficient to cause phenotypes but epistasis interactions modulate the expressivity and penetrance of the phenotype(s). Two models arise: a single primary driver or multiple primary drivers are sufficient to cause independent or same phenotypes. The other genes within the CNV modulate the penetrance and/or expressivity of the phenotype(s) primarily driven by the major driver(s).
activity of TBX1 have been found in rare DGS/VCFS non-deleted cases [74, 75] . These mutations could be considered as functionally equivalent to a deletion or a duplication of TBX1 respectively. Taken together, these data suggest that abnormal TBX1 dosage in either direction disrupts the same developmental pathways and result in similar developmental defects commonly ascribed to DGS/VCFS's phenotypic spectrum.
It [76] . The latter is supported by the detection of Tbx1 message in the frontal cortex and the hippocampus in mice [77] .
Similar to the 22qdel/dup CNV, a single gene has been proposed to be the major driver of mirrored phenotypes of the 16p11.2 CNV. Systematic screening of genes whose overexpression in zebrafish embryos causes microcephaly led to the identification of KCTD13 as a major driver for the neuroanatomical phenotypes of the 16p11.2 CNV [78 ] . Consistent with this observation, suppression of the same gene gave rise to macrocephalic embryos and the phenotypes were ascribed to changes in neurogenesis and apoptosis in the developing brain [78 ] . Genetic evidence supported this finding further. First, an atypical deletion of five genes, including KCTD13, segregated in a family with isolated ASD [79] ; second, a patient with ASD was found to harbor a de novo deletion of a portion of KCTD13 [78 ] . Further, epistatic analysis of KCTD13 in zebrafish embryos highlighted a contributory effect of two more genes from within the CNV, MVP and MAPK3 on the expressivity of the head size phenotype [78 ] ; notably, all three genes (KCTD13, MAPK3 and MVP) are present in the aforementioned 5-gene deletion [79] . Moreover, the patient with the de novo KCTD13 deletion also harboured an inherited heterozygous deletion distal to 16p11.2, suggesting a possible interaction with lesions outside this CNV [78 ] .
Mutations in RAI1 have been found in Smith-Magenis syndrome [80] suggesting that haploinsufficiency of RAI1 is probably responsible for the behavioral, neurologic, and craniofacial aspects of this syndrome. These phenotypes are also observed in dup patients with Potocki-Lupski syndrome. Further, increased anxiety and hyperactivity, growth retardation, and altered motor and sensory coordination, were observed in Rai1-overexpressant mice, recapitulating phenotypes observed in patients with 17p11.2 duplication [81] . These data suggest that over-expression or underexpression of RAI1 cause similar phenotypes that are pathognomonic of the two syndromes. The 17q11.2 del/dup patients also exhibit mirrored metabolic balance and sleep control disorders. Detailed analyses of the del and dup mice models recapitulated the mirrored metabolic phenotype observed in patients, whereas a defect of the circadian rhythm has only been found in the del mice to date [82] . Two mouse models have been generated subsequently to mimic overexpression and underexpression of RAI1 (TgRai1 and Rai1+/À respectively). These studies pointed to the fact that neither the duplication nor the deletion CNV-associated phenotypes can be attributed exclusively to RAI1 dosage. The Rai1+/À and del mice share the same phenotype, whereas the TgRai1 and dup mice phenotypes are discordant with an absence of changes in the serum chemistry and body composition in the TgRai1 mice compared to the dup mice [33 ] . As such, the mirrored metabolic and sleep control phenotypes seen in SMS/PTLS seem unlikely to be driven by Rai1 dosage alone. We speculate that copy number change of RAI1 and other genes in cis, such as the candidate SREBF1 [83] , with one of them exerting a synergistic or additive epistatic effect on the other, is required to fully manifest the reciprocal phenotypes of SMS and PTLS.
Genetic heterogeneity underlying nonreciprocal phenotypes
We have been unable to find an example in which two genes within a reciprocal CNV can drive a similar/ mirrored phenotype that is shared among patients with the same del/dup. Nonetheless, each type of lesion bears phenotypes, in addition to the reciprocal/similar manifestations, that are unique; in such instances, the composite phenotype of the CNV appears to be the synthesis of defects driven by more than one genes under a classical paradigm of a contiguous gene syndrome. For example, two genes have been implicated in the etiology of the Williams-Beuren syndrome, each gene responsible for a different phenotypic component of del/dup patients. Haploinsufficiency of elastin (ELN) is responsible for the supravalvular aortic stenosis and other arteriopathies but not cognitive defects in patients with WBS [84, 85] . Further, the identification of a small deletion including ELN and LIMK-1 in two families with partial WBS implicated LIMK-1 hemizygosity in impaired visuospatial constructive cognition [86] . Finally, suppression of GTF2I and GTF2IRD1 in mice recapitulated some WBS phenotypes such as microcephaly, retarded growth, and skeletal and craniofacial defects [87, 88] , suggesting that these two transcription factors are either possible drivers of the aforementioned phenotypes or modifiers exerting an epistatic effect to modulate cardiac and cognitive defects driven by the major drivers ELN and LIMK-1 respectively.
Such observations are also reported for other CNVs. For example, in addition to mirrored phenotypes observed in the 16p11.2 CNV, epilepsy has been found only in del patients [89, 90] . The recent finding of loss-of-function mutations in PRRT2, one of the 29 genes of the 16p11.2 CNV, in patients with epilepsy and seizures [91 ] suggests that PRRT2 is sufficient to cause epilepsy and seizures and KCTD13 is unlikely the only driver of the 16p11.2 phenotypes.
Reciprocal CNVs, variable penetrance and variable expressivity
A complicating factor of these post hoc analyses of CNV architecture is that most CNVs exhibit marked variability and non-penetrance. Moreover, phenotyping of siblings or parents is often missing or is partially reported; mild phenotypes are often not subjected to aCGH, leading to fewer duplication discoveries compared to deletion; and poor investigation and estimation of CNV burden in controls remains a source of concern. Despite these limitations, some potentially valuable observations are emerging that are likewise informing architecture of reciprocal CNVs. First, duplications appear to be more frequently inherited, while deletions are more frequently reported in patients to be de novo, suggesting that the latter are more likely to be penetrant [92] [93] [94] 95 ]. Second, duplications are generally milder and have greater variability in expressivity than deletions [92, 96] .
With regard to gene content, we are cautious in reaching conclusions about the relative prevalence of the three gene-based models (Figure 1 ). The handful of examples available to us predicts that the 'cis-epistasis' model is the most predominant. This would in turn predict that specifically for reciprocal phenotypes in reciprocal CNVs, there will be a single major driver influenced by proximal genetic content (as well as variation elsewhere in the genome). This is a testable hypothesis; for instance, the 16p11.2 data implicating haploinsufficiency of KCTD13 in ASD would predict a role for the same gene in the development of schizophrenia. More broadly, there are numerous examples of reciprocal CNVs in the morbid human genome whose genic etiology is not yet understood. For example, a 9-gene deletion on 1q21.1 is associated with microcephaly [13 ,27 ] , while the dup is associated with macrocephaly [13 ,27 ] ; once again our model would predict that dosage imbalance of a single transcript should account for both phenotypes.
Finally, a 'cis-epistasis' model ( Figure 1 ) also predicts that 'fixing' the dosage imbalance of a single driver gene within a CNV might represent an efficient means of identifying contributory interactors, which would be challenging to recognize using standard genetic or statistical methods. Initial data from the 16p11.2 CNV offer an indication that this approach is experimentally tractable but, naturally, such studies need to be reproduced for other regions. For this purpose, sensitizing the genetic background of appropriate model organisms to either haploinsufficiency or increased expression of the candidate CNV driver could be an useful template for the systematic screening for the ability of both cis and trans factors to change the penetrance and/or expressivity of driver-induced phenotypes. 
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